Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial
Identifieur interne : 001558 ( Main/Exploration ); précédent : 001557; suivant : 001559Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial
Auteurs : M. Spielmann [France] ; M. Tubiana-Hulin [France] ; M. Namer [France] ; H. Mansouri [France] ; P H Bougnoux [France] ; N. Tubiana-Mathieu [France] ; V. Lotz [France] ; J C Eymard [France]Source :
- British Journal of Cancer [ 0007-0920 ] ; 2002.
Abstract
The aim of this study, using a Fleming single-stage design, was to explore the efficacy and safety of Taxotere® 100 mg m−2 docetaxel and FEC 75 cyclophosphamide 500 mg m−2, fluorouracil 500 mg m−2 and epirubicin 75 mg m−2, in alternating and sequential schedules for the first-line treatment of metastatic breast cancer. One hundred and thirty-six women were randomly allocated, to one of three treatment regimens: DTX 100 plus FEC 75, alternated for eight courses (ALT); four courses of DTX 100 followed by four courses of FEC 75 (SEQ T); or four courses of FEC 75 followed by four courses of DTX 100 (SEQ F). One hundred and thirty-one women were evaluable for tumour response. Although the treatment outcome was equivalent in the two sequential arms and the alternating regimen (
© 2002
Url:
DOI: 10.1038/sj.bjc.6600165
PubMed: 11875727
PubMed Central: 2375306
Affiliations:
- France
- Centre-Val de Loire, Champagne-Ardenne, Grand Est, Limousin, Nouvelle-Aquitaine, Provence-Alpes-Côte d'Azur, Région Centre, Île-de-France
- Limoges, Nice, Paris, Reims, St Cloud, Tours, Villejuif
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000003
- to stream Pmc, to step Curation: 000003
- to stream Pmc, to step Checkpoint: 000150
- to stream Ncbi, to step Merge: 000046
- to stream Ncbi, to step Curation: 000046
- to stream Ncbi, to step Checkpoint: 000046
- to stream Main, to step Merge: 001599
- to stream Main, to step Curation: 001558
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial</title>
<author><name sortKey="Spielmann, M" sort="Spielmann, M" uniqKey="Spielmann M" first="M" last="Spielmann">M. Spielmann</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Institut Gustave Roussy, 39-53 rue Camille Desmoulins, 94805 Villejuif, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Gustave Roussy, 39-53 rue Camille Desmoulins, 94805 Villejuif</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tubiana Hulin, M" sort="Tubiana Hulin, M" uniqKey="Tubiana Hulin M" first="M" last="Tubiana-Hulin">M. Tubiana-Hulin</name>
<affiliation wicri:level="3"><nlm:aff id="aff2">Centre René Huguenin, 35 rue Dailly, 92210 St Cloud, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre René Huguenin, 35 rue Dailly, 92210 St Cloud</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">St Cloud</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Namer, M" sort="Namer, M" uniqKey="Namer M" first="M" last="Namer">M. Namer</name>
<affiliation wicri:level="3"><nlm:aff id="aff3">Centre A Lacassagne, 33 avenue de Valombrose, 06189 Nice Cedex 02, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre A Lacassagne, 33 avenue de Valombrose, 06189 Nice Cedex 02</wicri:regionArea>
<placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Nice</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mansouri, H" sort="Mansouri, H" uniqKey="Mansouri H" first="H" last="Mansouri">H. Mansouri</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Institut Gustave Roussy, 39-53 rue Camille Desmoulins, 94805 Villejuif, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Gustave Roussy, 39-53 rue Camille Desmoulins, 94805 Villejuif</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bougnoux, P H" sort="Bougnoux, P H" uniqKey="Bougnoux P" first="P H" last="Bougnoux">P H Bougnoux</name>
<affiliation wicri:level="3"><nlm:aff id="aff4">Hôpital Bretonneau, 2 bld Tonnellé, 37044 Tours Cedex 1, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Bretonneau, 2 bld Tonnellé, 37044 Tours Cedex 1</wicri:regionArea>
<placeName><region type="region" nuts="2">Centre-Val de Loire</region>
<region type="old region" nuts="2">Région Centre</region>
<settlement type="city">Tours</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tubiana Mathieu, N" sort="Tubiana Mathieu, N" uniqKey="Tubiana Mathieu N" first="N" last="Tubiana-Mathieu">N. Tubiana-Mathieu</name>
<affiliation wicri:level="3"><nlm:aff id="aff5">CHU Dupuytren, 2 avenue Martin Luther King, 87042 Limoges, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU Dupuytren, 2 avenue Martin Luther King, 87042 Limoges</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Limousin</region>
<settlement type="city">Limoges</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lotz, V" sort="Lotz, V" uniqKey="Lotz V" first="V" last="Lotz">V. Lotz</name>
<affiliation wicri:level="3"><nlm:aff id="aff6">Laboratoire Aventis, 46 Quai de la Rapée, 75601 Paris Cedex 12, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire Aventis, 46 Quai de la Rapée, 75601 Paris Cedex 12</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eymard, J C" sort="Eymard, J C" uniqKey="Eymard J" first="J C" last="Eymard">J C Eymard</name>
<affiliation wicri:level="3"><nlm:aff id="aff7">Centre Jean Godinot, 1 avenue du Général Koenig BP 171, 51056 Reims Cedex, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Jean Godinot, 1 avenue du Général Koenig BP 171, 51056 Reims Cedex</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Champagne-Ardenne</region>
<settlement type="city">Reims</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">11875727</idno>
<idno type="pmc">2375306</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375306</idno>
<idno type="RBID">PMC:2375306</idno>
<idno type="doi">10.1038/sj.bjc.6600165</idno>
<date when="2002">2002</date>
<idno type="wicri:Area/Pmc/Corpus">000003</idno>
<idno type="wicri:Area/Pmc/Curation">000003</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000150</idno>
<idno type="wicri:Area/Ncbi/Merge">000046</idno>
<idno type="wicri:Area/Ncbi/Curation">000046</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000046</idno>
<idno type="wicri:doubleKey">0007-0920:2002:Spielmann M:sequential:or:alternating</idno>
<idno type="wicri:Area/Main/Merge">001599</idno>
<idno type="wicri:Area/Main/Curation">001558</idno>
<idno type="wicri:Area/Main/Exploration">001558</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial</title>
<author><name sortKey="Spielmann, M" sort="Spielmann, M" uniqKey="Spielmann M" first="M" last="Spielmann">M. Spielmann</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Institut Gustave Roussy, 39-53 rue Camille Desmoulins, 94805 Villejuif, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Gustave Roussy, 39-53 rue Camille Desmoulins, 94805 Villejuif</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tubiana Hulin, M" sort="Tubiana Hulin, M" uniqKey="Tubiana Hulin M" first="M" last="Tubiana-Hulin">M. Tubiana-Hulin</name>
<affiliation wicri:level="3"><nlm:aff id="aff2">Centre René Huguenin, 35 rue Dailly, 92210 St Cloud, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre René Huguenin, 35 rue Dailly, 92210 St Cloud</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">St Cloud</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Namer, M" sort="Namer, M" uniqKey="Namer M" first="M" last="Namer">M. Namer</name>
<affiliation wicri:level="3"><nlm:aff id="aff3">Centre A Lacassagne, 33 avenue de Valombrose, 06189 Nice Cedex 02, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre A Lacassagne, 33 avenue de Valombrose, 06189 Nice Cedex 02</wicri:regionArea>
<placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Nice</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mansouri, H" sort="Mansouri, H" uniqKey="Mansouri H" first="H" last="Mansouri">H. Mansouri</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Institut Gustave Roussy, 39-53 rue Camille Desmoulins, 94805 Villejuif, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Gustave Roussy, 39-53 rue Camille Desmoulins, 94805 Villejuif</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bougnoux, P H" sort="Bougnoux, P H" uniqKey="Bougnoux P" first="P H" last="Bougnoux">P H Bougnoux</name>
<affiliation wicri:level="3"><nlm:aff id="aff4">Hôpital Bretonneau, 2 bld Tonnellé, 37044 Tours Cedex 1, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Bretonneau, 2 bld Tonnellé, 37044 Tours Cedex 1</wicri:regionArea>
<placeName><region type="region" nuts="2">Centre-Val de Loire</region>
<region type="old region" nuts="2">Région Centre</region>
<settlement type="city">Tours</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tubiana Mathieu, N" sort="Tubiana Mathieu, N" uniqKey="Tubiana Mathieu N" first="N" last="Tubiana-Mathieu">N. Tubiana-Mathieu</name>
<affiliation wicri:level="3"><nlm:aff id="aff5">CHU Dupuytren, 2 avenue Martin Luther King, 87042 Limoges, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHU Dupuytren, 2 avenue Martin Luther King, 87042 Limoges</wicri:regionArea>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Limousin</region>
<settlement type="city">Limoges</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lotz, V" sort="Lotz, V" uniqKey="Lotz V" first="V" last="Lotz">V. Lotz</name>
<affiliation wicri:level="3"><nlm:aff id="aff6">Laboratoire Aventis, 46 Quai de la Rapée, 75601 Paris Cedex 12, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire Aventis, 46 Quai de la Rapée, 75601 Paris Cedex 12</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eymard, J C" sort="Eymard, J C" uniqKey="Eymard J" first="J C" last="Eymard">J C Eymard</name>
<affiliation wicri:level="3"><nlm:aff id="aff7">Centre Jean Godinot, 1 avenue du Général Koenig BP 171, 51056 Reims Cedex, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Jean Godinot, 1 avenue du Général Koenig BP 171, 51056 Reims Cedex</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Champagne-Ardenne</region>
<settlement type="city">Reims</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">British Journal of Cancer</title>
<idno type="ISSN">0007-0920</idno>
<idno type="eISSN">1532-1827</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The aim of this study, using a Fleming single-stage design, was to explore the efficacy and safety of Taxotere® 100 mg m<sup>−2</sup>
docetaxel and FEC 75 cyclophosphamide 500 mg m<sup>−2</sup>
, fluorouracil 500 mg m<sup>−2</sup>
and epirubicin 75 mg m<sup>−2</sup>
, in alternating and sequential schedules for the first-line treatment of metastatic breast cancer. One hundred and thirty-six women were randomly allocated, to one of three treatment regimens: DTX 100 plus FEC 75, alternated for eight courses (ALT); four courses of DTX 100 followed by four courses of FEC 75 (SEQ T); or four courses of FEC 75 followed by four courses of DTX 100 (SEQ F). One hundred and thirty-one women were evaluable for tumour response. Although the treatment outcome was equivalent in the two sequential arms and the alternating regimen (<italic>P</italic>
=0.110, not significant), the response rate was less encouraging in the SEQ F arm (52.3%) than in the other two arms (71.1% for ALT and 70.5% for SEQ T), in which docetaxel was administered first. Time to progression was similar in the ALT, SEQ T and SEQ F arms (9.5, 9.3 and 10.4 months respectively). Grade 3–4 neutropenia was observed in nearly all patients; febrile neutropenia occurred in 9% (ALT), 16% (SEQ T) and 2% (SEQ F) of patients. Few patients (⩽9%) developed grade 3–4 non-haematological toxicities. Relative dose intensity was 97–99% for all regimens. All treatment regimens were active and well tolerated.</p>
<p><italic>British Journal of Cancer</italic>
(2002) <bold>86</bold>
, 692–697. DOI: <ext-link ext-link-type="doi" xlink:href="10.1038/sj/bjc/6600165">10.1038/sj/bjc/6600165</ext-link>
<ext-link ext-link-type="uri" xlink:href="www.bjcancer.com">www.bjcancer.com</ext-link>
</p>
<p>© 2002 <ext-link ext-link-type="uri" xlink:href="http://www.crc.org.uk">Cancer Research UK</ext-link>
</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Centre-Val de Loire</li>
<li>Champagne-Ardenne</li>
<li>Grand Est</li>
<li>Limousin</li>
<li>Nouvelle-Aquitaine</li>
<li>Provence-Alpes-Côte d'Azur</li>
<li>Région Centre</li>
<li>Île-de-France</li>
</region>
<settlement><li>Limoges</li>
<li>Nice</li>
<li>Paris</li>
<li>Reims</li>
<li>St Cloud</li>
<li>Tours</li>
<li>Villejuif</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Spielmann, M" sort="Spielmann, M" uniqKey="Spielmann M" first="M" last="Spielmann">M. Spielmann</name>
</region>
<name sortKey="Bougnoux, P H" sort="Bougnoux, P H" uniqKey="Bougnoux P" first="P H" last="Bougnoux">P H Bougnoux</name>
<name sortKey="Eymard, J C" sort="Eymard, J C" uniqKey="Eymard J" first="J C" last="Eymard">J C Eymard</name>
<name sortKey="Lotz, V" sort="Lotz, V" uniqKey="Lotz V" first="V" last="Lotz">V. Lotz</name>
<name sortKey="Mansouri, H" sort="Mansouri, H" uniqKey="Mansouri H" first="H" last="Mansouri">H. Mansouri</name>
<name sortKey="Namer, M" sort="Namer, M" uniqKey="Namer M" first="M" last="Namer">M. Namer</name>
<name sortKey="Tubiana Hulin, M" sort="Tubiana Hulin, M" uniqKey="Tubiana Hulin M" first="M" last="Tubiana-Hulin">M. Tubiana-Hulin</name>
<name sortKey="Tubiana Mathieu, N" sort="Tubiana Mathieu, N" uniqKey="Tubiana Mathieu N" first="N" last="Tubiana-Mathieu">N. Tubiana-Mathieu</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001558 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001558 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/France |area= LeHavreV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:2375306 |texte= Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:11875727" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a LeHavreV1
![]() | This area was generated with Dilib version V0.6.25. | ![]() |